Reckitt Bids To Delay Mucinex Competition With Bioequivalance Petition
This article was originally published in The Tan Sheet
Executive Summary
In an attempt to delay private-label competition for Mucinex OTC cough products, Reckitt Benckiser asks FDA to ensure potential generics meet the same bioequivalence across the 12-hour dosing interval as the branded product
You may also be interested in...
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics